Time To Add-On Medication Use for Patients with Type 2 Diabetes Mellitus (T2DM) Who Failed Metformin Monotherapy

被引：0
|
作者：
Qiu, Ying
Fu, Alex Z.
Radican, Larry
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A70 / +
页数：2
相关论文
共 50 条
  • [21] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS INSULIN-SECRETAGOGUES (SULPHONYLUREAS) OR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS AN ADD-ON TO METFORMIN IN IRELAND
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Nuhoho, S.
    Worbes-Cerezo, M.
    VALUE IN HEALTH, 2014, 17 (07) : A346 - A346
  • [22] Efficacy and Safety of Colesevelam HCl (COL) as an Add-On to Pioglitazone (PIO) for Type 2 Diabetes Mellitus (T2DM)
    Ford, Daniel M.
    Baz-Hecht, Merav
    Said, Nabil A.
    Tao, Ben
    Truitt, Kenneth E.
    Chou, Hubert S.
    DIABETES, 2013, 62 : A273 - A273
  • [23] Safety and Tolerability of Linagliptin and Metformin in Combination for Patients with Type 2 Diabetes Mellitus (T2DM)
    Ross, Stuart A.
    Haak, Thomas
    Patel, Sanjay
    Thiemann, Sandra
    Schumacher, Helmut
    Meinicke, Thomas
    DIABETES, 2014, 63 : A277 - A277
  • [24] Efficacy of Teneligliptin as a Fourth Add-On in Patients with Type 2 Diabetes Mellitus (T2DM) Poorly Controlled on Triple Drug Therapy
    Panikar, Vijay
    Joshi, Shashank R.
    Vadgama, Jimit
    Kamat, Tejas
    Nasikkar, Nikhil
    Deogaonkar, Narayan
    Jain, Chandni
    DIABETES, 2017, 66 : A340 - A340
  • [25] The Usage of Metformin Despite of Existing Contraindications in Type 2 Diabetes Mellitus (T2DM) Patients
    Kosmalski, Marcin
    Drozdowska, Agata
    Drzewoski, Jozef
    DIABETES, 2011, 60 : A311 - A312
  • [26] Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
    Jeon, Ja Young
    Ha, Kyoung Hwa
    Kim, Dae Jung
    DIABETES & METABOLISM JOURNAL, 2021, 45 (04) : 505 - 514
  • [27] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [28] Empagliflozin as Add-On to Metformin Plus Sulfonylurea (SU) for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A279 - A279
  • [29] Empaglifl ozin (EMPA) Compared with Glimepiride (GLIM) as Add-On to Metformin (MET) for 4 Years in Patients with Type 2 Diabetes (T2DM)
    Ridderstrale, Martin
    Robert, Knut
    Toorawa, Andersen
    Woerle, Hans J.
    Salsali, Afshin
    DIABETES, 2016, 65 : A47 - A48
  • [30] Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy
    Fu, A. Z.
    Qiu, Y.
    Davies, M. J.
    Radican, L.
    Engel, S. S.
    DIABETES OBESITY & METABOLISM, 2011, 13 (08): : 765 - 769
12345